title: Active stents in diabetic patients.
abstract: In the treatment of coronary stenosis, evolution after PTCA is not as good in diabetic patients compared to non diabetic ones, whatever the treatment used. We now have data of large clinical studies which show good results of drug loaded stents in diabetic patients, especially with either a cytostatic drug (sirolimus) or a cytotoxic one (paclitaxol). In the RAVEL study, among the 44 diabetic patients, 19 had sirolimus stenting with a restenosis rate of 0% vs a restenosis rate of 40% for the 25 patients with standard stents. In the 279 diabetic patient group of the SIRIUS study, the restenosis rate (50% or more stenosis rate) was 17.6% when sirolimus stenting was used vs 50.5% for the patients with standard stenting and at 9 months and target lesion revascularisation was from 22.3% with bare metal stents, compared to 6.9% with sirolimus eluting stents. In the TAXUS IV study, the advantage was evident in diabetic patients with a restenosis rate 80% lower in patients treated with oral anti diabetic therapy and 82% in patients treated with insulin. In the TAXUS VI study, the target lesion revascularisation rate of diabetic patients was 2.6% when taxus MR (modified release) was used, vs 22.6% with standard stents. The event which until now made PTCA different from surgery was restenosis, especially in diabetic patients. The analysis of use of recent active stenting registries has shown that diabetic patients have now much better long term results than previously reported.
authors.affiliation: Laboratoire d'hémodynamique et cardiologie interventionelle, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France. gerard.drobinski@psl.ap-hop-paris.fr
authors.forename: G
authors.initials: G
authors.lastname: Drobinski
authors.forename: C
authors.initials: C
authors.lastname: Le Feuvre
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D023903:Coronary Restenosis; D023921:Coronary Stenosis / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents; D020123:Sirolimus; D015607:Stents
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus